First Berlin Equity Research publishes independent analysis of Cyxone
Cyxone (publ.), a clinical stage biotech company developing first-in-class drugs for diseases of the immune system, announces today that the research company First Berlin Equity Research has published an independent analysis report of Cyxone.
The independent analysis covers the first nine months of 2020 and a pipeline update. In the analysis, which was published on 17 December 2020, First Berlin reviewed the company’s potential with an expected but continued positive outcome.
The report in English can be read in its entirety on the Cyxone’s website.Contact
Tara Heitner, CEO
Tel: +46 70 781 88 08
211 22 Malmö, Sweden
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, email@example.com. For more information, please visit www.cyxone.comOpen First Berlin Equity Research's Analysis